Recent Articles

Glioblastoma—Unraveling the Threads: A Q&A with Drs. Mark Gilbert and Terri Armstrong of the NIH Neuro-Oncology Branch

| August 3, 2017 | 0 Comments

Glioblastoma—Unraveling the Threads: A Q&A with Drs. Mark Gilbert and Terri Armstrong of the NIH Neuro-Oncology Branch Progress against the brain cancer glioblastoma has been slow. Drs. Mark Gilbert and Terri Armstrong of NCI’s Neuro-Oncology Branch discuss why and what’s being done to change that.See Original Article

Continue Reading

Survivors of Breast Cancer Differ on Who Should Manage Follow-Up Care

| August 2, 2017 | 0 Comments

Survivors of Breast Cancer Differ on Who Should Manage Follow-Up Care Many survivors of early-stage breast cancer prefer that their oncologist handle aspects of routine medical care usually overseen by primary care practitioners, leading to concerns about gaps in care.See Original Article

Continue Reading

Two New Therapies Approved by FDA for Advanced Kidney Cancer

| July 30, 2017 | 0 Comments

Two New Therapies Approved by FDA for Advanced Kidney Cancer The FDA has approved two drugs, cabozantinib and lenvatinib, for patients whose advanced kidney cancers have progressed after prior treatment with antiangiogenic therapies. See Original Article

Continue Reading

FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic Leukemia

| July 25, 2017 | 0 Comments

FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic Leukemia FDA changed its accelerated approval of blinatumomab (Blincyto) for some patients with acute lymphoblastic leukemia to a full approval and expanded the approved indications for its use.See Original Article

Continue Reading

FDA Clears Wider Use of Cooling Cap to Reduce Hair Loss during Chemotherapy

| July 21, 2017 | 0 Comments

FDA Clears Wider Use of Cooling Cap to Reduce Hair Loss during Chemotherapy The FDA has cleared a cooling cap—a device designed to reduce hair loss during chemotherapy called the DigniCap Scalp Cooling System—for use by patients with any type of solid tumor. See Original Article

Continue Reading

Two-Drug Combination Approved for Lung Cancers with BRAF Mutations

| July 18, 2017 | 0 Comments

Two-Drug Combination Approved for Lung Cancers with BRAF Mutations FDA approved the combination of dabrafenib (Tafinlar®) and trametinib (Mekinist®) for patients the treatment of metastatic non-small cell lung cancer (NSCLC) that has an alteration in the BRAF gene called the V600E mutation.See Original Article

Continue Reading

NCI’s Technology Transfer Center—Moving Inventions and Ideas from the Lab to Patients: An Interview with Dr. Michael Salgaller

| July 17, 2017 | 0 Comments

NCI’s Technology Transfer Center—Moving Inventions and Ideas from the Lab to Patients: An Interview with Dr. Michael Salgaller An interview with Dr. Michael Salgaller about how NCI’s Technology Transfer Center helps to move new technologies developed by NCI and NIH scientists from the lab to the bedside.See Original Article

Continue Reading

New Rituximab Formulation Approved for Some Lymphomas, Leukemia

| July 14, 2017 | 0 Comments

New Rituximab Formulation Approved for Some Lymphomas, Leukemia The FDA has approved a new formulation of rituximab, Rituxan Hycela, that reduces treatment administration time for patients with several types of blood cancer. See Original Article

Continue Reading

Large Study Verifies Cancer Risk for Women Carrying BRCA1 or BRCA2 Mutations

| July 12, 2017 | 0 Comments

Large Study Verifies Cancer Risk for Women Carrying BRCA1 or BRCA2 Mutations Results from the first large prospective study of breast and ovarian cancer risk in women with inherited mutations in the BRCA 1 or BRCA2 genes confirm the high risks estimated from earlier, retrospective studies.See Original Article

Continue Reading

NCI's CURE Program—21 Years of Increasing Diversity in the Biomedical Workforce

| July 11, 2017 | 0 Comments

NCI's CURE Program—21 Years of Increasing Diversity in the Biomedical Workforce NCI’s CURE program recently celebrated its 21st anniversary of providing training and other support to improve the diversity of people involved in cancer research and care. See Original Article FDA Approves Talimogene Laherparepvec to Treat Metastatic Melanoma The FDA has approved the first oncolytic […]

Continue Reading